A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Key facts
- Where
- Anderlecht, Bonheiden, and Brugge, BelgiumSee the 3 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06727604, who can take part
Where in Belgium
- Hopital ErasmeAnderlecht, BelgiumTaking people
- ImeldaBonheiden, BelgiumTaking people
- Az St-Jan Brugge-Oostende A.V.Brugge, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Immunovant Sciences GmbH
- Trial code
- NCT06727604EU 2024-516020-33-00
- Record updated
- 25 August 2026
- Original description
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.Read full original descriptionShow less
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine [T3] or free triiodothyronine [FT3]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.
Inclusion: Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures; Male or female participants aged ≥ 18 years; Participants with diagnosis of GD who are hyperthyroid despite ATD treatment; Other, more specific inclusion criteria are defined in the protocol.
Exclusion: Have previously been successfully treated with radioactive iodine (RAI) therapy or have undergone total thyroidectomy; Have an autoimmune disease other than GD requiring treatment that, in the Investigator's judgment, puts the participant at undue risk; Have moderate-to-severe active thyroid eye disease (TED) and are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation; Additional exclusion criteria are defined in the protocol.